Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab

  • Bertrand Coiffier
  • , Weimin Li
  • , Erin D. Henitz
  • , Jayaprakash D. Karkera
  • , Reyna Favis
  • , Dana Gaffney
  • , Alice Shapiro
  • , Panteli Theocharous
  • , Yusri A. Elsayed
  • , Helgi Van De Velde
  • , Michael E. Schaffer
  • , Evgenii A. Osmanov
  • , Xiaonan Hong
  • , Adriana Scheliga
  • , Jiri Mayer
  • , Fritz Offner
  • , Simon Rule
  • , Adriana Teixeira
  • , Joanna Romejko-Jarosinska
  • , Sven De Vos
    • Michael Crump, Ofer Shpilberg, Pier Luigi Zinzani, Andrew Cakana, Dixie Lee Esseltine, George Mulligan, Deborah Ricci

نتاج البحث: نشر في مجلة › مقالة › مراجعة النظراء

16 اقتباسات (Scopus)

بصمة

أدرس بدقة موضوعات البحث “Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab'. فهما يشكلان معًا بصمة فريدة.

Keyphrases

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology

Neuroscience